Gene | Primers | Length (bp) |
---|---|---|
IL-6 | F: CCCCAATTTCCAATGCTCTCC |
141 |
IL-10 | F: TTTAAGGGTTACTTGGGTTGCC |
106 |
IL-1β | F: TCAAATCTCGCAGCAGCACATC |
206 |
GAPDH | F: CCTCGTCCCGTAGACAAAATG |
133 |
Isolate number | Species | GenBank accession number | Similarity (%) |
---|---|---|---|
4 | MT482589 | 99.73 | |
5 | MT482590 | 99.93 | |
6 | MT482591 | 99.93 | |
8 | MT482586 | 99.93 | |
10 | MT482587 | 99.80 | |
11 | MT463724 | 99.93 | |
12 | MT482592 | 99.93 | |
13 | MT482593 | 99.93 | |
14 | MT482594 | 99.93 | |
16 | MT482595 | 99.93 | |
18 | MT482596 | 99.93 | |
20 | MT482588 | 99.93 | |
22 | MT463726 | 99.86 | |
25 | MT463727 | 99.86 | |
26 | MT482597 | 99.93 | |
27 | MT482598 | 99.93 | |
28 | MT482599 | 99.93 | |
29 | MT482600 | 99.93 | |
30 | MT482601 | 99.93 | |
33 | MT482602 | 99.93 | |
38 | MT482603 | 99.79 | |
39 | MT482604 | 99.86 | |
305 | MT463725 | 99.30 |
Trial | A | B | C | D | Inhibitory activity (%) |
---|---|---|---|---|---|
1 | 1 | 1 | 3 | 2 | 70.00 |
2 | 1 | 2 | 1 | 1 | 82.50 |
3 | 1 | 3 | 2 | 3 | 38.00 |
4 | 2 | 1 | 2 | 1 | 71.50 |
5 | 2 | 2 | 3 | 3 | 7.50 |
6 | 2 | 3 | 1 | 2 | 31.00 |
7 | 3 | 1 | 1 | 3 | 43.00 |
8 | 3 | 2 | 2 | 2 | 30.00 |
9 | 3 | 3 | 3 | 1 | 25.50 |
K1 | 63.50 | 61.50 | 52.17 | 59.83 | |
K2 | 36.67 | 40.00 | 46.33 | 43.67 | |
K3 | 32.83 | 31.50 | 34.33 | 29.50 | |
30.67 | 30.00 | 17.84 | 30.33 | ||
Optimum technologies | A1B1C1D1 | 93.18 ± 1.19 | |||
SS | 0.334 | 0.294 | 0.096 | 0.279 | |
df | 2 | 2 | 2 | 2 | |
F | 10.969 | 9.637 | 3.156 | 9.143 | |
Significance |
Trial | A | B | C | D | Inhibitory activity (%) |
---|---|---|---|---|---|
1 | 1 | 1 | 3 | 2 | 73.57 |
2 | 1 | 2 | 1 | 1 | 63.28 |
3 | 1 | 3 | 2 | 3 | 54.32 |
4 | 2 | 1 | 2 | 1 | 71.93 |
5 | 2 | 2 | 3 | 3 | 35.05 |
6 | 2 | 3 | 1 | 2 | 62.74 |
7 | 3 | 1 | 1 | 3 | 64.79 |
8 | 3 | 2 | 2 | 2 | 24.18 |
9 | 3 | 3 | 3 | 1 | 54.39 |
K1 | 63.72 | 70.10 | 63.60 | 63.20 | |
K2 | 56.57 | 40.84 | 53.50 | 53.50 | |
K3 | 47.79 | 57.15 | 51.39 | 51.39 | |
15.94 | 29.26 | 12.22 | 11.81 | ||
Optimum technologies | A1B1C1D1 | 75.33 ± 2.89 | |||
SS | 0.076 | 0.258 | 0.057 | 0.048 | |
df | 2 | 2 | 2 | 2 | |
F | 74.785 | 252.387 | 55.709 | ||
Significance |
Isolate | Survival rate (%) | Adhesion rate (%) |
---|---|---|
12.42 ± 2.84 | 6.94 ± 0.27 | |
9.10 ± 1.12 | 6.91 ± 0.11 | |
5.86 ± 0.52 | 6.09 ± 0.39 | |
8.82 ± 2.50 | 6.37 ± 0.28 |
Level | A ( |
B ( |
C ( |
D ( |
---|---|---|---|---|
1 | 108 | 108 | 108 | 108 |
2 | 109 | 109 | 109 | 109 |
3 | 1010 | 1010 | 1010 | 1010 |
Isolate | Viable bacteria count (109CFU/ml) | α-amylase inhibitory activities (%) | α-glucosidase inhibitory activities (%) | |
---|---|---|---|---|
8 | 1.71 ± 0.47 |
49.93 ± 2.06 |
12.39 ± 3.05 |
|
10 | 2.61 ± 0.38 |
56.72 ± 8.78 |
12.60 ± 3.22 |
|
20 | 2.29 ± 0.73 |
17.33 ± 5.03 |
11.45 ± 4.18 |
|
22 | 1.22 ± 0.47 |
62.29 ± 0.44 |
14.89 ± 0.38 |
|
25 | 1.84 ± 0.70 |
51.81 ± 3.65 |
15.32 ± 0.89 |
|
4 | 2.11 ± 0.64 |
20.96 ± 4.95 |
28.51 ± 5.73 |
|
5 | 2.15 ± 0.25 |
16.84 ± 8.34 |
15.91 ± 0.91 |
|
6 | 2.93 ± 0.28 |
44.94 ± 3.72 |
19.33 ± 1.02 |
|
11 | 2.55 ± 0.30 |
58.40 ± 1.68 |
52.63 ± 3.07 |
|
12 | 0.93 ± 0.66 |
44.05 ± 4.51 |
17.98 ± 9.09 |
|
13 | 2.85 ± 0.69 |
51.86 ± 4.20 |
17.60 ± 1.84 |
|
14 | 2.96 ± 0.52 |
37.19 ± 7.29 |
4.93 ± 0.94 |
|
16 | 3.92 ± 0.38 |
32.29 ± 9.59 |
15.35 ± 8.28 |
|
18 | 2.16 ± 0.80 |
27.35 ± 7.43 |
15.94 ± 1.38 |
|
26 | 2.53 ± 0.98 |
49.95 ± 6.54 |
15.60 ± 2.62 |
|
27 | 2.49 ± 0.92 |
41.39 ± 2.52 |
20.83 ± 4.58 |
|
28 | 3.59 ± 0.50 |
47.92 ± 3.62 |
20.53 ± 0.17 |
|
29 | 2.23 ± 0.67 |
46.74 ± 3.31 |
4.99 ± 0.56 |
|
30 | 2.41 ± 1.43 |
55.38 ± 0.48 |
15.69 ± 1.93 |
|
33 | 1.70 ± 0.90 |
47.49 ± 2.27 |
14.19 ± 2.13 |
|
38 | 3.16 ± 0.77 |
50.59 ± 3.12 |
8.10 ± 4.18 |
|
39 | 1.89 ± 0.59 |
37.77 ± 8.18 |
5.24 ± 0.89 |
|
305 | 2.04 ± 0.51 |
57.48 ± 5.04 |
51.79 ± 1.13 |